Interestingly, we found that the high-risk group was significantly enriched for patients with cancer relapse or death (P = 0.00095, Fisher’s exact test), while the low risk group significantly comprised of patients with CIN, CIMP, MSI, and BRAF mutations (P = 0.00034, 0.0063, 8.59e−11, 0.0013, respectively, Fisher’s exact tests; Fig. 3a). Here, BRAF is linked to cancer.